[Bi-directional ventricular tachycardia and pheochromocytoma: a case report]. / Tachycardie ventriculaire bidirectionnelle et phéochromocytome: a propos d'un cas.

We present the case of a 48 year old woman who was admitted to our university hospital in cardiogenic shock with bi-directional ventricular tachycardia degenerating into polymorphic venricular tachycardia which resolved spontaneously. Investigation revealed healthy coronary arteries but severe left ventricular dysfunction due to akinesia involving the entire base. There was a rapid improvement within several days. The diagnosis of bilateral phaeochromocytoma was made on the biochemistry and CT scan of the adrenals.

[Anthracycline-induced heart failure aggravated by pregnancy. Survival after cardiac assistance with artificial heart device and heart transplantation]. / Myocardiopathie aux anthracyclines décompensée par une grossesse. Guérison par transplantation cardiaque après assistance temporaire par coeur artificiel.

We report a case of a young woman suffering from a steady anthracycline-induced myocardiopathy with a decreased left ventricular function on echocardiography. A pregnancy was initiated, without worsening of the cardiopathy until 34 weeks. Nine days after delivery, an acute heart failure was observed leading to heart transplantation after cardiac assistance with heart cardiac device. As pregnancy is an extended stress test for a chronic failing heart, a multidisciplinary decision of pregnancy initiation and follow up should be preferred in pre and postpartum period, when such a cardiopathy exists.

[Pregnancy and dilated or hypertrophic cardiomyopathies]. / Grossesse et cardiomyopathies dilatées ou hypertrophiques.

The risk of pregnancy in women with hypertrophic (HCM) or dilated (DCM) cardiomyopathy may be difficult to assess. Haemodynamic changes occur during pregnancy which may destabilize the underlying cardiac disease. Nevertheless, with or without pharmacological support and with vigilance at the time of childbirth, the outcome of pregnancies in patients with HCM is usually good without extra-mortality. On the other hand, complications often occur in symptomatic patients with DCM and left ventricular dysfunction. Pregnancy is not advisable in this group of patients. Finally, pregnancy may be responsible for a specific type of cardiomyopathy, peripartum cardiomyopathy, a rare condition occurring in the last month or during the 5 following months, which has an unpredictable outcome to complete recovery, myocardial sequellae or aggravation leading to cardiac transplantation or death. These patients are at high risk in future pregnancies.

[Hypertrophic cardiomyopathy. Long-term clinical development in a regional cohort of 243 patients]. / Cardiomyopathie hypertrophique. Evolution clinique à long terme d'une cohorte régionale de 243 patients.

This retrospective study was undertaken to assess the long-term clinical outcome of hypertrophic cardiomyopathy (HCM) in a regional cohort of 243 patients aged 40.4 years on average at the time of diagnosis and followed up for 12.3 +/- 8.1 years. Forty-one deaths were recorded during the follow-up period directly related to HCM (including 20 sudden deaths and 17 deaths due to cardiac failure), an annual cardiac mortality rate of 1.37%. In multivariate analysis, two factors were associated with extra mortality: occurrence of the first symptoms before the age of 20 (RR x 2.35) (p = 0.006) and NYHA functional classes III: IV at the latest clinical assessment (p = 0.005). The risk of sudden death increased significantly with septal wall thickness: RR x 2.34 (p = 0.05), RR x 3.27 (p = 0.007) and RR x 3.67 (p = 0.02) respectively, for septal thickness equal to or greater than 25, 30 and 35 mm. Eighty-three patients (34%) had major cardiovascular events (sudden death, congestive cardiac failure, cerebrovascular accident) during follow-up. However, at the latest clinical assessment, 79% were relatively unaffected by their disease, without treatment (12%) or with drug therapy alone (60%). In a minority of patients (28%) a more aggressive therapeutic approach was necessary: cardiac pacing (N = 48), implantable cardiac defibrillators (N = 2) myomectomy (N = 27) or cardiac transplantation (N = 6). The authors conclude that HCM is a complex disease, less serious than initially thought in the majority of patients, but the cause of major cardiovascular events and premature deaths which still remain difficult to prevent.

[Cure of superacute eosinophilic myocarditis treated by temporary circulatory assistance]. / Guérison d'une myocardite suraiguë à éosinophiles traitée par assistance circulatoire temporaire.

The authors report the case of a 31 year old woman, admitted as an emergency for acute myopericarditis, in cardiogenic shock. Echocardiography showed severe left ventricular dysfunction associated with concentric biventricular hypertrophy with increased echogenicity of the myocardial walls. Poor response to treatment with intravenous inotropic drugs led to referral for biventricular circulatory assistance with a Biomedicus pump, which was withdrawn on the 9th day after recovery of normal left ventricular function. Myocardial biopsies showed massive interstitial inflammation with a predominance of eosinophilic cells suggesting a hypersensitivity reaction. Steroid therapy was prescribed when the results of biopsy were known and stopped after 6 months. This case emphasises the value of echocardiography and myocardial biopsy in diagnosis and treatment of acute myocarditis with cardiogenic shock.

[Can one die of sorrow?]. / Peut-on mourir de chagrin?

The authors report the case of a 49 year old woman who, on two occasions four years apart, presented with cardiogenic shock following the same type of intense emotional stress. Acute left ventricular systolic dysfunction in the initial phase regressed completely with drugs. A diagnostic investigation excluded atheromatous coronary artery disease, myocarditis and pheochromocytoma. Two hypotheses remained: prolonged coronary spasm causing myocardial stunning or acute catecholaminergic cardiomyopathy secondary to the stress.

[Surgery in heart failure (without transplantation)]. / Chirurgie dans l'insuffisance cardiaque (hors transplantation).

Cardiac transplant remains the treatment of reference for end-stage cardiac insufficiency. The very great disparity between the number of grafts available and the number of patients eligible to be included on the transplant list drives some of them to contemplate a surgical alternative in order to improve their clinical condition and to delay as much as possible the date of transplant. The objective is to treat surgically one or several of the lesions causing the cardiac insufficiency. It could be valvular surgery, coronary surgery or a combination of both, ventricular remodelling or cardiomyoplasty. It is coronary revascularisation surgery which gives the most spectacular results on condition that it is aimed at the myocardial zones for which viability has been demonstrated by stress echocardiography or a PET scan.